Patents Assigned to The Regents of the Univ. of California
-
Publication number: 20220348737Abstract: The present invention provides: nanoparticles including a compound that includes porous silica and at least one high-atom selected from the group consisting of gadolinium atoms, iodine atoms, gold atoms, silver atoms, and platinum atoms; and a pharmaceutical composition for radiation treatment, useful for treatment of solid tumors, etc., and including these nanoparticles and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 25, 2020Publication date: November 3, 2022Applicants: KYOTO UNIVERSITY, NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY, THE REGENTS OF THE UNIV. OF CALIFORNIAInventors: Fuyuhiko TAMANOI, Kotaro MATSUMOTO, Hiroyuki SAITOH, Ayumi SENOUCHI, Toshiki TAJIMA
-
Patent number: 6872817Abstract: Methods and compositions for chromosome-specific staining are provided. Compositions comprise heterogeneous mixtures of labeled nucleic acid fragments having substantially complementary base sequences to unique sequence regions of the chromosomal DNA for which their associated staining reagent is specific. Methods include methods for making the chromosome-specific staining compositions of the invention, and methods for applying the staining compositions to chromosomes.Type: GrantFiled: June 5, 1995Date of Patent: March 29, 2005Assignee: The Regents of the Univ. of CaliforniaInventors: Joe W. Gray, Daniel Pinkel
-
Publication number: 20040167014Abstract: A novel proton exchange membrane fuel cell with nanostructured components with higher precious metal utilization rate at the electrodes, higher power density, and lower cost. Aligned arrays of carbon nanotubes, either single wall or multiwall, are prepared by catalyzed chemical vapor deposition (CVD), or plasma assisted CVD and used as support for catalyst. Solubilized perfluorosulfonate ionomer membrane is incorporated into the spare space between nanotubes to form a 4-phase boundary of gas, metal, proton conductor, and electron conductor. By assembling the as-prepared electrodes with perfluorosulfonate ionomer membrane, backing layers and electron collectors, proton exchange membrane fuel cells are developed.Type: ApplicationFiled: November 13, 2003Publication date: August 26, 2004Applicant: The Regents of the Univ. of California, Office of Technology Transfer, University of CaliforniaInventors: Yushan Yan, Cheng Wang
-
Patent number: 6544528Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.Type: GrantFiled: November 7, 2000Date of Patent: April 8, 2003Assignees: University of Florida Research Foundation, Inc., Regents of the Univ. of CaliforniaInventor: Janet K. Yamamoto
-
Patent number: 6349649Abstract: The perforating device for use in completing a well includes a case, an explosive charge contained in the case, and a generally bowl-shaped liner. The liner is positioned adjacent the explosive charge and has non-uniforrn thickness along its length. The liner further includes a protruding portion near its tip. In another configuration, the liner includes a hole near its tip to expose a portion of the explosive charge.Type: GrantFiled: September 13, 1999Date of Patent: February 26, 2002Assignees: Schlumberger Technology Corp., Regents of Univ. of CaliforniaInventors: Jerome J. Jacoby, James E. Brooks, Clifford L. Aseltine
-
Patent number: 6277593Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described.Type: GrantFiled: October 7, 1998Date of Patent: August 21, 2001Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of CaliforniaInventors: David M. Valenzuela, Nancy Y. Ip, Henryk D. Cudny, George D. Yancopoulos, Richard M. Harland, William C. Smith, Teresa Lamb, Anne Knecht
-
Patent number: 6274119Abstract: A method for labeling &bgr;-amyloid plaques and neurofibrillary tangles in vivo and in vitro, comprises contacting a compound of formula (I): with mammalian tissue.Type: GrantFiled: August 20, 1999Date of Patent: August 14, 2001Assignee: The Regents of the Univ. of CaliforniaInventors: Jorge R. Barrio, Andrej Petric, Nagichettiar Satyamurthy, Gary W. Small, Gregory M. Cole, Sung-Cheng Huang
-
Patent number: 6262254Abstract: An efficient, regiocontrolled approach to the synthesis of 8-fluoropurines by direct fluorination of purines with dilute elemental fluorine, or acetyl hypofluorite, is provided. In a preferred embodiment, a purine compound is dissolved in a polar solvent and reacted with a dilute mixture of F2 in He or other inert gas.Type: GrantFiled: November 25, 1998Date of Patent: July 17, 2001Assignee: The Regents of Univ. of CaliforniaInventors: Jorge R. Barrio, Nagichettiar Satyamurthy, Mohammad Namavari, Michael E. Phelps
-
Patent number: 6166039Abstract: Methods for treatment of peripheral hyperalgesia are provided, comprising administering compositions containing an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(.rho.-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-p iperidinebutyramide hydrochloride is preferred for use in the methods.Type: GrantFiled: November 24, 1998Date of Patent: December 26, 2000Assignee: Regents of the Univ. of CaliforniaInventor: Tony L. Yaksh
-
Patent number: 6090811Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenic inflammatory properties exhibited by the bis-indole compounds and their analogs.Type: GrantFiled: July 16, 1999Date of Patent: July 18, 2000Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of CaliforniaInventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
-
Patent number: 6074835Abstract: The present invention provides a method of diagnosing ulcerative colitis (UC) in a subject suspected of having inflammatory bowel disease by by obtaining a sample from the individual; contacting the sample with human histone H1, or pANCA-reactive fragment thereof, under conditions suitable to form a complex of human histone H1, or pANCA-reactive fragment thereof, and antibody to human histone H1; and detecting the presence or absence of the complex, where the presence of the complex indicates that the individual has UC. The invention also provides related methods of diagnosing a perinuclear anti-neutrophil cytoplasmic antibody positive (pANCA-positive) clinical subtype of UC in a patient with UC. In addition, the invention further provides methods of determining susceptibility to UC in an individual.Type: GrantFiled: April 11, 1997Date of Patent: June 13, 2000Assignees: Regents of the Univ. of California, Cedars-Sinai Medical CenterInventors: Johnathan Braun, Stephan R. Targan, Mark Eggena
-
Patent number: 6075007Abstract: Described are modified Noggin muteins, compositions comprising the muteins, and DNA or RNA sequences comprising coding (sense) or antisense sequences for the muteins.Type: GrantFiled: July 17, 1997Date of Patent: June 13, 2000Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of CaliforniaInventors: Aris Economides, Neil E. Stahl, Richard M. Harland
-
Patent number: 5955462Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenicinflammatory properties exhibited by the bis-indole compounds and their analogs.Type: GrantFiled: October 31, 1997Date of Patent: September 21, 1999Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of CaliforniaInventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
-
Patent number: 5821124Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described. Hybridoma cell lines and antibodies that bind to the dorsal growth inducing factor noggin, having the amino acid sequence set forth in SEQ ID NO:2, are also described.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignees: Regeneron Pharmaceuticals, Inc., Regents of Univ. of CaliforniaInventors: David M. Valenzuela, George D. Yancopoulos, Richard M. Harland, William C. Smith
-
Patent number: 5667968Abstract: Photoreceptor injury or cell death (retinal degeneration) is prevented by the introduction into the living mammalian eye of specific, survival-promoting factors. These specific factors prevent damage and degeneration of photoreceptors when introduced into the living eye prior to, during or after exposure to the damaging effects of light and delay photoreceptor damage caused by inherited disease.Type: GrantFiled: November 4, 1994Date of Patent: September 16, 1997Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of CaliforniaInventors: Matthew M. LaVail, Roy H. Steinberg, George D. Yancopoulos
-
Patent number: 5589881Abstract: A low-noise FET amplifier is connected to amplify output charge from a che coupled device (CCD). The FET has its gate connected to the CCD in common source configuration for receiving the output charge signal from the CCD and output an intermediate signal at a drain of the FET. An intermediate amplifier is connected to the drain of the FET for receiving the intermediate signal and outputting a low-noise signal functionally related to the output charge signal from the CCD. The amplifier is preferably connected as a virtual ground to the FET drain. The inherent shunt capacitance of the FET is selected to be at least equal to the sum of the remaining capacitances.Type: GrantFiled: November 9, 1994Date of Patent: December 31, 1996Assignee: The Regents of the Univ. of California Office of Technology TransferInventors: Mark E. Dunham, David W. Morley
-
Patent number: 5581566Abstract: A system of sending and receiving gateways interconnects high speed data interfaces, e.g., HIPPI interfaces, through fiber optic links, e.g., a SONET network. An electronic stripe distributor distributes bytes of data from a first interface at the sending gateway onto parallel fiber optics of the fiber optic link to form transmitted data. An electronic stripe collector receives the transmitted data on the parallel fiber optics and reforms the data into a format effective for input to a second interface at the receiving gateway. Preferably, an error correcting syndrome is constructed at the sending gateway and sent with a data frame so that transmission errors can be detected and corrected in a real-time basis. Since the high speed data interface operates faster than any of the fiber optic links the transmission rate must be adapted to match the available number of fiber optic links so the sending and receiving gateways monitor the availability of fiber links and adjust the data throughput accordingly.Type: GrantFiled: January 6, 1995Date of Patent: December 3, 1996Assignee: The Regents of the Univ. of California Office of Technology TransferInventors: Wallace B. St. John, David H. DuBois
-
Patent number: 5578909Abstract: A coupled-cavity drift-tube linac (CCDTL) combines features of the Alvarez drift-tube linac (DTL) and the .pi.-mode coupled-cavity linac (CCL). In one embodiment, each accelerating cavity is a two-cell, 0-mode DTL. The center-to-center distance between accelerating gaps is .beta..lambda., where .lambda. is the free-space wavelength of the resonant mode. Adjacent accelerating cavities have oppositely directed electric fields, alternating in phase by 180 degrees. The chain of cavities operates in a .pi./2 structure mode so the coupling cavities are nominally unexcited. The CCDTL configuration provides an rf structure with high shunt impedance for intermediate velocity charged particles, i.e., particles with energies in the 20-200 MeV range.Type: GrantFiled: July 15, 1994Date of Patent: November 26, 1996Assignee: The Regents of the Univ. of CaliforniaInventor: James H. Billen
-
Patent number: 5571675Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: November 5, 1996Assignees: Genentech, Inc., Regents of the Univ. of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5571893Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: August 5, 1994Date of Patent: November 5, 1996Assignees: Genentech, Inc., Regents of the Univ. of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood